The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Insulin degludec (Tresiba®) has been rejected for use in the treatment of diabetes mellitus in adults. The manufacturer failed to make a sufficiently robust economic case.
Insulin glargine (Lantus®) has been accepted for restricted use in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. The restriction recommends use in patients with Type 1 diabetes when efforts to achieve better glycaemic control result in unacceptable levels of nocturnal hypoglycaemia or to aid carer administration. In patients with Type 2 diabetes use is recommended for patients who experience recurrent episodes of hypoglycaemia or require assistance with their insulin injections.
Timothy grass pollen allergen (GRAZAX®) has been rejected for use as a disease-modifying treatment of grass pollen induced rhinitis and conjunctivitis in adults and children. The manufacturer failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.